![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » MITSUBISHI PHARMA IN-LICENSES CNS COMPOUND TO BRAINCELLS
MITSUBISHI PHARMA IN-LICENSES CNS COMPOUND TO BRAINCELLS
August 14, 2006
San Diego-based drug discovery and development company BrainCells Inc. has in-licensed a clinical-stage compound from Mitsubishi Pharma Corp. (MPC) that BCI will reposition and develop for the treatment of central nervous system (CNS) diseases, including mood disorders. BioSpectrum (http://www.biospectrumasia.com/content/110806JPN1333.asp)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct